TRACTION-2
The purpose of our Phase 2 trial, TRACTION-2, is to determine if our once-daily, oral, investigational precision medicine, GFB-887, is beneficial for people with high levels of protein in their urine due to focal segmental glomerulosclerosis (FSGS), diabetic nephropathy (DN) or treatment resistant minimal change disease (TR-MCD).
To learn more about TRACTION-2, visit TractionClinicalTrial.com or clinicaltrials.gov